104 related articles for article (PubMed ID: 9397179)
1. 5-HT1B receptor antagonist properties of novel arylpiperazide derivatives of 1-naphthylpiperazine.
Jorand-Lebrun C; Pauwels PJ; Palmier C; Moret C; Chopin P; Perez M; Marien M; Halazy S
J Med Chem; 1997 Nov; 40(24):3974-8. PubMed ID: 9397179
[TBL] [Abstract][Full Text] [Related]
2. The selective 5-HT1B receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo.
Gaster LM; Blaney FE; Davies S; Duckworth DM; Ham P; Jenkins S; Jennings AJ; Joiner GF; King FD; Mulholland KR; Wyman PA; Hagan JJ; Hatcher J; Jones BJ; Middlemiss DN; Price GW; Riley G; Roberts C; Routledge C; Selkirk J; Slade PD
J Med Chem; 1998 Apr; 41(8):1218-35. PubMed ID: 9548813
[TBL] [Abstract][Full Text] [Related]
3. F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine.
John GW; Pauwels PJ; Perez M; Halazy S; Le Grand B; Verscheure Y; Valentin JP; Palmier C; Wurch T; Chopin P; Marien M; Kleven MS; Koek W; Assie MB; Carilla-Durand E; Tarayre JP; Colpaert FC
J Pharmacol Exp Ther; 1999 Jul; 290(1):83-95. PubMed ID: 10381763
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and serotonergic activity of 3-[2-(pyrrolidin-1-yl)ethyl]indoles: potent agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B receptor.
Sternfeld F; Guiblin AR; Jelley RA; Matassa VG; Reeve AJ; Hunt PA; Beer MS; Heald A; Stanton JA; Sohal B; Watt AP; Street LJ
J Med Chem; 1999 Feb; 42(4):677-90. PubMed ID: 10052975
[TBL] [Abstract][Full Text] [Related]
5. SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2'methyl-4'-(5-methyl-1,2,3-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): a novel, potent and selective 5-HT1B receptor antagonist.
Scott C; Langmead CJ; Clarke KL; Wyman P; Smith PW; Starr KR; Dawson LA; Price GW; Hagan JJ; Watson J
Neuropharmacology; 2006 Jun; 50(8):984-90. PubMed ID: 16546225
[TBL] [Abstract][Full Text] [Related]
6. 3-(Piperazinylpropyl)indoles: selective, orally bioavailable h5-HT1D receptor agonists as potential antimigraine agents.
Chambers MS; Street LJ; Goodacre S; Hobbs SC; Hunt P; Jelley RA; Matassa VG; Reeve AJ; Sternfeld F; Beer MS; Stanton JA; Rathbone D; Watt AP; MacLeod AM
J Med Chem; 1999 Feb; 42(4):691-705. PubMed ID: 10052976
[TBL] [Abstract][Full Text] [Related]
7. (+)-WAY 100135, a partial agonist, at native and recombinant 5-HT1B/1D receptors.
Davidson C; Ho M; Price GW; Jones BJ; Stamford JA
Br J Pharmacol; 1997 Jun; 121(4):737-42. PubMed ID: 9208142
[TBL] [Abstract][Full Text] [Related]
8. SB-224289--a novel selective (human) 5-HT1B receptor antagonist with negative intrinsic activity.
Selkirk JV; Scott C; Ho M; Burton MJ; Watson J; Gaster LM; Collin L; Jones BJ; Middlemiss DN; Price GW
Br J Pharmacol; 1998 Sep; 125(1):202-8. PubMed ID: 9776361
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological analysis of G-protein activation mediated by guinea-pig recombinant 5-HT1B receptors in C6-glial cells: similarities with the human 5-HT1B receptor.
Pauwels PJ; Wurch T; Palmier C; Colpaert FC
Br J Pharmacol; 1998 Jan; 123(1):51-62. PubMed ID: 9484854
[TBL] [Abstract][Full Text] [Related]
10. Structure-affinity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides, a new class of 5-hydroxytryptamine7 receptor agents.
Leopoldo M; Berardi F; Colabufo NA; Contino M; Lacivita E; Niso M; Perrone R; Tortorella V
J Med Chem; 2004 Dec; 47(26):6616-24. PubMed ID: 15588097
[TBL] [Abstract][Full Text] [Related]
11. [N-methyl-3H3]AZ10419369 binding to the 5-HT1B receptor: in vitro characterization and in vivo receptor occupancy.
Maier DL; Sobotka-Briner C; Ding M; Powell ME; Jiang Q; Hill G; Heys JR; Elmore CS; Pierson ME; Mrzljak L
J Pharmacol Exp Ther; 2009 Jul; 330(1):342-51. PubMed ID: 19401496
[TBL] [Abstract][Full Text] [Related]
12. 8-Piperazinyl-2,3-dihydropyrrolo[3,2-g]isoquinolines: potent, selective, orally bioavailable 5-HT1 receptor ligands.
Heightman TD; Gaster LM; Pardoe SL; Pilleux JP; Hadley MS; Middlemiss DN; Price GW; Roberts C; Scott CM; Watson JM; Gordon LJ; Holland VA; Powles J; Riley GJ; Stean TO; Trail BK; Upton N; Austin NE; Ayrton AD; Coleman T; Cutler L
Bioorg Med Chem Lett; 2005 Oct; 15(19):4370-4. PubMed ID: 16039851
[TBL] [Abstract][Full Text] [Related]
13. Benzylimidazolines as h5-HT1B/1D serotonin receptor ligands: a structure-affinity investigation.
Law H; Dukat M; Teitler M; Lee DK; Mazzocco L; Kamboj R; Rampersad V; Prisinzano T; Glennon RA
J Med Chem; 1998 Jun; 41(13):2243-51. PubMed ID: 9632357
[TBL] [Abstract][Full Text] [Related]
14. Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy of arylpiperazine derivatives at the central 5-HT3 receptors.
Cappelli A; Anzini M; Vomero S; Canullo L; Mennuni L; Makovec F; Doucet E; Hamon M; Menziani MC; De Benedetti PG; Bruni G; Romeo MR; Giorgi G; Donati A
J Med Chem; 1999 May; 42(9):1556-75. PubMed ID: 10229626
[TBL] [Abstract][Full Text] [Related]
15. 5-HT1D receptor agonist properties of novel 2-[5-[[(trifluoromethyl)sulfonyl]oxy]indolyl]ethylamines and their use as synthetic intermediates.
Barf TA; de Boer P; Wikström H; Peroutka SJ; Swensson K; Ennis MD; Ghazal NB; McGuire JC; Smith MW
J Med Chem; 1996 Nov; 39(24):4717-26. PubMed ID: 8941384
[TBL] [Abstract][Full Text] [Related]
16. Facilitation and inhibition of male rat ejaculatory behaviour by the respective 5-HT1A and 5-HT1B receptor agonists 8-OH-DPAT and anpirtoline, as evidenced by use of the corresponding new and selective receptor antagonists NAD-299 and NAS-181.
Hillegaart V; Ahlenius S
Br J Pharmacol; 1998 Dec; 125(8):1733-43. PubMed ID: 9886765
[TBL] [Abstract][Full Text] [Related]
17. Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors.
Watson J; Brough S; Coldwell MC; Gager T; Ho M; Hunter AJ; Jerman J; Middlemiss DN; Riley GJ; Brown AM
Br J Pharmacol; 1998 Dec; 125(7):1413-20. PubMed ID: 9884068
[TBL] [Abstract][Full Text] [Related]
18. Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 1. Mapping the central 5-HT3 receptor binding site by arylpiperazine derivatives.
Cappelli A; Anzini M; Vomero S; Mennuni L; Makovec F; Doucet E; Hamon M; Bruni G; Romeo MR; Menziani MC; De Benedetti PG; Langer T
J Med Chem; 1998 Feb; 41(5):728-41. PubMed ID: 9513601
[TBL] [Abstract][Full Text] [Related]
19. Binding of O-alkyl derivatives of serotonin at human 5-HT1D beta receptors.
Glennon RA; Hong SS; Bondarev M; Law H; Dukat M; Rakhi S; Power P; Fan E; Kinneau D; Kamboj R; Teitler M; Herrick-Davis K; Smith C
J Med Chem; 1996 Jan; 39(1):314-22. PubMed ID: 8568822
[TBL] [Abstract][Full Text] [Related]
20. Novel derivatives of 2-pyridinemethylamine as selective, potent, and orally active agonists at 5-HT1A receptors.
Vacher B; Bonnaud B; Funes P; Jubault N; Koek W; Assié MB; Cosi C; Kleven M
J Med Chem; 1999 May; 42(9):1648-60. PubMed ID: 10229633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
